MS Bioworks

Executive Summary

MS Bioworks is a contract research organization (CRO) based in Cambridge, Massachusetts, specializing in high-end protein mass spectrometry and proteomics services. Founded in 2015, the company operates a state-of-the-art laboratory and serves a global clientele of academic, biotech, and pharmaceutical researchers. Their services provide highly accurate analytical data critical for biological research and drug development, positioning them as a reliable partner in the proteomics space. With a focus on quality and precision, MS Bioworks has carved out a niche in the competitive CRO market, particularly for complex protein analysis. The company benefits from the growing demand for proteomics services driven by advances in biologics and personalized medicine. Their technical expertise and established reputation in Cambridge's biotech hub provide a strong foundation for steady revenue growth. While private and not disclosing financials, MS Bioworks is well-positioned to capture increasing outsourcing trends. Key growth drivers include expansion of service offerings and potential strategic partnerships. However, the CRO sector faces competition from larger players, requiring continuous technological investment. Overall, MS Bioworks represents a stable, specialized service provider with moderate growth prospects.

Upcoming Catalysts (preview)

• Q3 2026Launch of advanced mass spectrometry platform for high-throughput proteomics70% success
• Q4 2026Expansion into biologics characterization services (e.g., intact mass analysis)60% success
• Q2 2027Strategic partnership with a major pharmaceutical company for long-term contract50% success